---
title: "Tellgen: First repurchase of 0.13% of the company's shares"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/254996358.md"
description: "Tellgen announced that on August 28, 2025, the company first implemented a share repurchase of 211,200 shares through a dedicated stock repurchase account via centralized bidding, accounting for 0.13% of the company's current total share capital. The highest transaction price for the repurchased shares was RMB 29.34 per share, the lowest transaction price was RMB 27.3 per share, and the total amount paid was RMB 5.9071 million. This repurchase complies with the company's established repurchase plan and relevant laws and regulations"
datetime: "2025-08-28T11:46:08.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/254996358.md)
  - [en](https://longbridge.com/en/news/254996358.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/254996358.md)
generator: "portal-rs"
---

# Tellgen: First repurchase of 0.13% of the company's shares

Tellgen announced that on August 28, 2025, the company repurchased 211,200 shares through a dedicated stock repurchase account via centralized bidding, accounting for 0.13% of the company's current total share capital. The highest transaction price for the repurchased shares was RMB 29.34 per share, and the lowest transaction price was RMB 27.3 per share, with a total payment amount of RMB 5.9071 million. This repurchase complies with the company's established repurchase plan and relevant laws and regulations

### Related Stocks

- [300642.CN](https://longbridge.com/en/quote/300642.CN.md)

## Related News & Research

- [CARsgen FY26 H1 net loss narrows to RMB 70.84 million; revenue rises 21.49% to RMB 61.92 million](https://longbridge.com/en/news/296243257.md)
- [13:49 ETVascarta Outlines Proposed Mechanistic Link Between VAS-101's (Vasceptor®) Vascular and Red Blood Cell Effects in Sickle Cell Disease](https://longbridge.com/en/news/296524035.md)
- [07:55 ETSAPPHIRE LENSES & WINDOWS PROTECT SENSITIVE ELECTRO-OPTICAL SYSTEMS](https://longbridge.com/en/news/296224371.md)
- [04:20 ETSphingoTec to Engage with Clinical and Industry Partners at Major 2026 Conferences](https://longbridge.com/en/news/296322953.md)
- [Dicot Pharma says three LIB-01 erectile dysfunction trial abstracts win oral slots at SMSNA meeting](https://longbridge.com/en/news/296312317.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**